Skip to content
← Full study record

NCT00021255 · MORE INFO

Limitations, agreements, and source contact

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer · Source last updated 2016-11-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
Contact-US@sanofi.com
organization
Sanofi
title
Trial Transparency Team
Complete source fields
certain Agreement
other Details
If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
Contact-US@sanofi.com
organization
Sanofi
title
Trial Transparency Team

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice